PCRX vs. AMPX
PCRX (Pacira BioSciences, Inc.) and AMPX (Amprius Technologies Inc.) are both stocks. PCRX operates in Drug Manufacturers - Specialty & Generic (Healthcare), while AMPX operates in Electrical Equipment & Parts (Industrials). Over the past 3 years, PCRX returned -17.04%/yr vs 41.64%/yr for AMPX. At a 0.04 correlation, their price movements are largely independent.
Performance
PCRX vs. AMPX - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, PCRX achieves a -13.76% return, which is significantly lower than AMPX's 175.54% return.
PCRX
- 1D
- 0.31%
- 1M
- -9.60%
- YTD
- -13.76%
- 6M
- -7.73%
- 1Y
- -15.45%
- 3Y*
- -17.04%
- 5Y*
- -18.20%
- 10Y*
- -7.19%
AMPX
- 1D
- -5.11%
- 1M
- 6.67%
- YTD
- 175.54%
- 6M
- 88.72%
- 1Y
- 720.38%
- 3Y*
- 41.64%
- 5Y*
- —
- 10Y*
- —
PCRX vs. AMPX - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
PCRX Pacira BioSciences, Inc. | -13.76% | 37.37% | -44.16% | -12.61% | -28.86% |
AMPX Amprius Technologies Inc. | 175.54% | 181.79% | -47.07% | -33.29% | -20.70% |
Correlation
The correlation between PCRX and AMPX is -0.02, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | -0.02 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.04 |
Correlation (All Time) Calculated using the full available price history since Sep 16, 2022 | 0.04 |
Fundamentals
PCRX:
$913.11M
AMPX:
$2.98B
PCRX:
$0.21
AMPX:
-$0.31
PCRX:
1.32
AMPX:
31.16
PCRX:
1.40
AMPX:
27.21
PCRX:
$734.86M
AMPX:
$90.26M
PCRX:
$427.72M
AMPX:
$16.37M
PCRX:
$95.04M
AMPX:
-$17.72M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
PCRX vs. AMPX — Risk / Return Rank
PCRX
AMPX
PCRX vs. AMPX - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Pacira BioSciences, Inc. (PCRX) and Amprius Technologies Inc. (AMPX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| PCRX | AMPX | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | -0.42 | 6.70 | -7.12 |
Sortino ratioReturn per unit of downside risk | -0.36 | 4.07 | -4.43 |
Omega ratioGain probability vs. loss probability | 0.96 | 1.49 | -0.53 |
Calmar ratioReturn relative to maximum drawdown | -0.52 | 15.67 | -16.20 |
Martin ratioReturn relative to average drawdown | -1.07 | 38.53 | -39.60 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| PCRX | AMPX | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | -0.42 | 6.70 | -7.12 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | -0.40 | — | — |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | -0.15 | — | — |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.16 | 0.18 | -0.02 |
Drawdowns
PCRX vs. AMPX - Drawdown Comparison
The maximum PCRX drawdown since its inception was -90.19%, roughly equal to the maximum AMPX drawdown of -94.49%. Use the drawdown chart below to compare losses from any high point for PCRX and AMPX.
Loading charts...
Drawdown Indicators
| PCRX | AMPX | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -90.19% | -94.49% | +4.30% |
Max Drawdown (1Y)Largest decline over 1 year | -29.61% | -46.41% | +16.80% |
Max Drawdown (3Y)Largest decline over 3 years | -71.53% | -93.11% | +21.58% |
Max Drawdown (5Y)Largest decline over 5 years | -85.67% | — | — |
Max Drawdown (10Y)Largest decline over 10 years | -85.67% | — | — |
Current DrawdownCurrent decline from peak | -81.29% | -5.11% | -76.18% |
Average DrawdownAverage peak-to-trough decline | -50.01% | -55.27% | +5.26% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 14.42% | 18.84% | -4.42% |
Volatility
PCRX vs. AMPX - Volatility Comparison
The current volatility for Pacira BioSciences, Inc. (PCRX) is 10.03%, while Amprius Technologies Inc. (AMPX) has a volatility of 44.99%. This indicates that PCRX experiences smaller price fluctuations and is considered to be less risky than AMPX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| PCRX | AMPX | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 10.03% | 44.99% | -34.96% |
Volatility (6M)Calculated over the trailing 6-month period | 28.70% | 78.26% | -49.56% |
Volatility (1Y)Calculated over the trailing 1-year period | 37.03% | 108.48% | -71.45% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 45.60% | 128.83% | -83.23% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 46.90% | 128.83% | -81.93% |
Dividends
PCRX vs. AMPX - Dividend Comparison
Neither PCRX nor AMPX has paid dividends to shareholders.
Financials
PCRX vs. AMPX - Financials Comparison
This section allows you to compare key financial metrics between Pacira BioSciences, Inc. and Amprius Technologies Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
PCRX vs. AMPX - Profitability Comparison
PCRX - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Pacira BioSciences, Inc. reported a gross profit of 0.00 and revenue of 177.38M. Therefore, the gross margin over that period was 0.0%.
AMPX - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Amprius Technologies Inc. reported a gross profit of 5.74M and revenue of 28.54M. Therefore, the gross margin over that period was 20.1%.
PCRX - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Pacira BioSciences, Inc. reported an operating income of 6.90M and revenue of 177.38M, resulting in an operating margin of 3.9%.
AMPX - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Amprius Technologies Inc. reported an operating income of -6.69M and revenue of 28.54M, resulting in an operating margin of -23.4%.
PCRX - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Pacira BioSciences, Inc. reported a net income of 7.08M and revenue of 177.38M, resulting in a net margin of 4.0%.
AMPX - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Amprius Technologies Inc. reported a net income of -5.05M and revenue of 28.54M, resulting in a net margin of -17.7%.
Frequently Asked Questions
PCRX and AMPX have a correlation of -0.02, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
AMPX has higher volatility (44.99%) compared to PCRX (10.03%). In terms of maximum drawdown, PCRX dropped -90.19% vs AMPX's -94.49%.
AMPX currently has the higher Sharpe Ratio (6.70 vs -0.42), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for PCRX and AMPX
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer